SANTA MONICA, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the third quarter ended September 30, 2022, after the financial markets close on Monday, November 14, 2022.
The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Monday, November 14, 2022. To access the call, please dial 1-877-407-0792 in the U.S. or 1-201-689-8263 outside the U.S. and provide the conference ID number: 13732765. To access the live webcast, please visit https://viavid.webcasts.com/starthere.jsp?ei=1569474&tp_key=bb26315c9c. Following the live webcast, an archived version of the call will be available on the website.
Monday November 14 @ 4:30 pm ET | |
Domestic: | 1-877-407-0792 |
International: | 1-201-689-8263 |
Conference ID: | 13732765 |
Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1569474&tp_key=bb26315c9c |
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com.
For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
batkins@opiant.com
Revolutionary vibration device offers pain relief for finger pricks, GLP-1 shots, and wellness injections BOCA…
Vaughan, Ontario--(Newsfile Corp. - April 22, 2025) - Delota Corp. (CSE: NIC) (FSE: S62) ("Delota"…
MILL CREEK, Wash., April 22, 2025 /PRNewswire/ -- Laxco, Inc., a trailblazer in cutting-edge optical and…
Ryan El-Hosseiny to set the record straight Live TODAY in Miami Beach MIAMI BEACH, Fla.,…
NEW YORK, April 22, 2025 /PRNewswire/ -- Healthee, the AI-powered platform transforming the health benefits experience,…
UTRECHT, Netherlands, April 22, 2025 /PRNewswire/ -- At Reuters Events Pharma 2025 in Barcelona, industry leaders…